Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors

NCT03975387 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT03975387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03975387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
July 11, 2019
Completion date
August 15, 2024
Enrollment
106 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor